NCT05257161 (SIBERIA-2) is a NA clinical trial of Emboshield NAV6™ in Patients With Aterosclerotic Carotid Stenosis, sponsored by Meshalkin Research Institute of Pathology of Circulation.

Who is sponsoring NCT05257161?

NCT05257161 is sponsored by Meshalkin Research Institute of Pathology of Circulation.

What drugs are being tested in NCT05257161?

Interventions in NCT05257161: Emboshield NAV6™, Mo.Ma™.

What condition does NCT05257161 study?

NCT05257161 studies Patients With Aterosclerotic Carotid Stenosis, Symptomatic Patients (Stenosis > 50%), Asymptomatic Patients (Stenosis ≥80%).

Is NCT05257161 still recruiting?

NCT05257161 is currently recruiting now. Last updated 25 February 2022.

Last reviewed 2022-02-25 · How we verify

NCT05257161: SIBERIA-2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Carotid Revascularization With MicroNet Covered Stent Comparing Early Neurological Outcomes With Distal Versus Proximal EPS

Recruiting now NA Last updated 25 February 2022

What this trial tests

NA trial testing Emboshield NAV6™ in Patients With Aterosclerotic Carotid Stenosis in 366 participants. Currently enrolling.

Timeline

1 November 2021

Primary endpoint
1 November 2026

1 January 2027

Quick facts

Lead sponsor	Meshalkin Research Institute of Pathology of Circulation
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	366
Start date	1 November 2021
Primary completion	1 November 2026
Estimated completion	1 January 2027
Sites	1 location across Russia

Drugs / interventions tested

Emboshield NAV6™
Mo.Ma™

Conditions studied

Patients With Aterosclerotic Carotid Stenosis — all drugs for Patients With Aterosclerotic Carotid Stenosis →
Symptomatic Patients (Stenosis > 50%) — all drugs for Symptomatic Patients (Stenosis > 50%) →
Asymptomatic Patients (Stenosis ≥80%) — all drugs for Asymptomatic Patients (Stenosis ≥80%) →

Sponsor

Meshalkin Research Institute of Pathology of Circulation

Who can join

Adults 45 to 80, any sex, with Patients With Aterosclerotic Carotid Stenosis or Symptomatic Patients (Stenosis > 50%). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The SIBERIA study demonstrated a clear advantage of CGuard stent implantation over the existing classical stent when using a distal anti-embolic device. At the same time, there is no Level 1 evidence for a difference between the proximal and distal anti-embolic device for the CGuard stent.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Meshalkin Research Institute of Pathology of Circulation trials

Trials by the same sponsor.

NCT07372196 — Left Bundle Branch Pacing in Patients With Hypertrophic Cardiomyopathy After Myectomy · NA · recruiting
NCT06443931 — Cryoablation of Intercostal Nerves for Pain Management in Early Postoperative Period in Patients With Minimally Invasive · NA · completed
NCT06069115 — Radiotherapy Exposed Lung Injury: Effect on Functioning - Cohort · recruiting
NCT05856461 — Pulmonary Artery Denervation in Patients With Atrial Fibrillation and Group 2 of Pulmonary Hypertension · NA · unknown
NCT05643664 — The Role of Artificial Intelligence in the Treatment of Abdominal Aortic Aneurysms · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05257161 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Meshalkin Research Institute of Pathology of Circulation
Last refreshed: 25 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05257161.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing